Intratumoral heterogeneity

  • Filip Vuletić Doctor of Medicine, University of Zagreb, School of Medicine
  • Vendy Zajec
  • Lovorka Batelja Vuletić
  • Sven Seiwerth


virtual slides in your article

Intratumoral heterogeneity has become the main obstacle in treatment of malignant diseases. Although it has been known for decades, that several morphologically different sub-populations of tumor cells do exist within an individual malignant tumor, the interest in this issue has been limited for a long time. Now-a-days, the interest in this field is raising again with the emergence of need for a more detailed analysis of tumor cell characteristics. It is essential to integrate and extend our knowledge of intratumoral heterogeneity and to sufficiently elucidate this fact because intratumoral heterogeneity is considered one of the main reasons for drug resistance and development of progressive metastases. New light has been shed on the significance of discovering new methods for determining intratumoral heterogeneity. These should assist to presume cancer progression including invasion, metastasis, drug resistance, disease relapse and to administer the most adequate treatment. Although no doubt exists that intratumoral heterogeneity is evident in several, if not most malignant tumors, its origin has not been confirmed, and still remains to be discussed. So far, two theories have been proposed that try to explain the development of intratumoral heterogeneity: the idea of ​​‘cancer stem cells’ and the idea of ongoing cancer cell mutations that implement different cell clones. Both theories are discussed as mutually restricted hypotheses in the literature; however, they play an essential role in explaining the occurrence of tumor cell heterogeneity.

Author Biography

Sven Seiwerth

Institute of Pathology, School of medicine University of Zagreb, Salata 3, 10 000 Zagreb Croatia 


1. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer res. 1978;38(9):2651-60.
2. Welch DR. Tumor Heterogeneity--A 'Contemporary Concept' Founded on Historical Insights and Predictions. Cancer Res. 2016;76(1):4-6.
3. Futreal PA, Gerliner M, Pusztai L, Swanton C, Yap TA. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med. 2012;4:127-110.
4. Brown JS, Bui MM, Gatenby RA, Lloyd MC, Minor ES, Rejniak KA. Pathology to enhance precision medicine in oncology: lessons from landscape ecology. Adv Anat Pathol. 2015;22(4):267-72.
5. Brooke ES, Efsevia V. Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. J Gastrointest Oncol. 2015; 6(6): 668–675.
6. Beca F, Polyak K. Intratumor Heterogeneity in Breast Cancer. Adv Exp Med Biol. 2016;882:169-89.
7. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle. 2007;6:2332–8.
8. De Bruin EC, McGranahan N, Swanton C. Analysis of intratumor heterogeneity unravels lung cancer evolution. Moll Cell Oncol. 2015;2(3):e985549.
9. Assenov Y, Bogatyrova O, Brocks D, Brors B, Feuerbach L, Korbel J i sur. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014;8(3):798-806.
10. Berman BP, Cai Y, Chang C, Dihn HQ, Hao JJ, Koeffler HP i sur. S Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat Genet. 2016;48(12):1500-1507.
11. Maley CC, Merlo LM, Pepper JW, Reid BJ. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6:924–35.
12. Clarke MF, Morrison MJ, Reya T,Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
13. Al- Hajj M, Clarke MF. Self-reneval and solid tumor stem cells. Oncogene. 2004;23:7274-82.
14. Bapat SA. Evolution of cancer stem cells. Semin Cancer Biol. 2007;17:204-13.
15. Barcellos-Hoff MH, Bissell MJ, Park CC. The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000;6:324-329.
16. Lowe SW, Luambio A. The microcosmos of cancer. 2012;482:347-55.
17. Campell IG, Haviv I, Polyak K. Co-evolution of tumor cells and their microenvironment.Trends Genet. 2009;25:30-38.
18. Alfrarouk KO, Brown JS, Bui MM, Gatenby RA, Lloyd MC, Verduzco D. Vascular measurement correlate with estrogen receptor status. BMC Cancer. 2014;14:279.
19. Chen HY, Chan WK, Chang GC, Ho BC, Kuo ML, Li KC i sur. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433-40.
20. Bohm F, Egger M, Frick L, Friemel J, Moch H, Rechsteiner M. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res. 2015;21(8):1951-61.
21. Atanackovic D, BokemeyerC, Clauditz TS, Grob TJ, Hoenig T, Izbicki JR. Frequent intratumoral heterogenity of EGFR gene copy gain in non-smal cell lung cancer. Lung Cancer. 2013;79(3):221-7.
22. Fujimoto K, Gotoda T, Grabsch HI, Hale MD, Hara M, Itoi T i sur. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19: 553–560.
23. Brčić L, Bura M, Ćorić M, Kusić Z, Ladika-Davidović B, Seiwerth S. Heterogeneity of DNA content in laryngeal squamous cell carcinoma in relation to histopatological variables. Acta Otolaryngol. 2009;129(7):768-73.
24. Coons SW, Johnson PC. Regional heterogeneity in the DNA content of human gliomas. Cancer. 1993 Nov 15;72(10):3052-60.
25. Cherdyntseva NV, Denisov EV, Litvyakov NV, Slonimskaya EM, Perelmuter VM, Slonimskaya EM, i sur. The presence of alveolar structures in invasive ductal NOS breast carcinoma is associated with lymph node metastasis. Diagn Cytopathol. 2013;41(3):279-82.
26. Cherdyntseva NV, Denisov EV, Garbukov EY, Geraschenko TS, Perelmuter VM, Slonimskaya EM. Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression. Sci Rep. 2014;4:4709.
27. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol. 2000;36(2-3):193-207.
28. Graham CH, Kerbel RS, Kobayashi H, Kapitain SJ, Man S,Teicher BA. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A. 1993;90(8):3294-8.
29. Callaghan R, Mellor HR. Accumulation and distribution of doxorubicin in tumor spheroids: the influence of caidity and expression of P-glycoprotein. Cancer Chemoter Pharmacol. 2011;68:1179-1190.
30. Brown JS, Bui MM, Gatenby RA, Lloyd MC, Minor ES, Rejniak KA. Pathology to enhance precision medicine in oncology: lessons from landscape ecology. Adv Anat Pathol. 2015;22(4):267-72.
31. Albarghach N, Corcos L, Hatt M, Le Rest CC, Metges JP, Tixier F. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52(3):369-78.
32. Chang S, Kim SJ, Pak K. Determination of regional lymph node status using (18) F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumor heterogeneity. Br. J . Radiol. 2016;22:20150673.
33. Blount PL, Finley JC, Galipeau PC, Maley CC, Paulson TG, Rabinovitch PS. Genetic clonal diversity predics progression to oesophageal adenocarcinoma. Nat Genet. 2006;38:468-473.
34. Bliven SF, Faulkner LE, Leith JT, Michelson S. Growth properties of artificial heterogenous human colon tumors. Cancer Res. 1987;47:1045-1051.
35. Gulczynski J, Majewska H, Lapinska-Szumczyk S,Supernat A, Wojciech B, Wydra D,i sur. Tumor Heterogeneity at Protein Level as an Independent Prognostic Factor in Endometrial Cancer. Translational Oncology. 2014;7(5):613-9.
36. Demanes DJ, Huang J, Mesko S, Kamrava M. Kupelian P, Wang PC. Quantifying the ki-67 heterogeneity profile in prostate cancer. Prostate Cancer. 2013;2013:1–5.
37. Aristu J, Diez-Valle R, Echeveste J, Idoate MA, Lozano MD. Biological and clinical significance of the intratumour heterogeneity of PTEN protein expression and the corresponding molecular abnormalities of the PTEN gene in glioblastomas. Neuropathol Appl Neurobiol. 2014;40(6):736-46.
38. Trump A, Wiestler OD. Mechanisms of disease: cancer stem cells–targeting the evil twin. Nat. Clin. Pract. Oncol. 2008;5: 337–347.
39. Brown R, Glasspool R.M., Teodoridis JM. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 2006;94:1087–1092.
40. Azizian N, Brandstetter K, Classon M, Fischbach MA, Lee DY, Li B. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80.
41. Casa AJ, Cui X, Dearth RK, Lee AV, Litzenburger BC. The type I insulin-like gorwth receptor patway: a key player in cancer therapeutic resistance. Front. Biosci. 2008;13:3273-3287.
42. Pollax M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer. 2008;8:915-928.
43. Douillard JY, Oliner KS, Siena S. Pantimumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023-1034.
44. Decker T, Heinemann V, Weikersthal LF. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patient with metastatic colorectal cancer (FIRE-3): a randomised, open label, phase 3 trial. Lancet. Oncol. 2014;15:1065-1075.
45. Botti G, Ciardiello F, Colluci G, Esposito C, Fenizia F, Lambiase M. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in CAPRI GOIM trial. Ann Oncol. 2015;26(8):1710-4.
46. Nicolson GL, Yeatman TJ. Molecular basis of tumor progresion: mechanisms of organs-specific tumor metastasis. Semin Surg Oncol. 1993;9(3):256-263.
47. Dawson SJ, Ignatidis M. Circulating tumorcells and circulating tumor DNA for precision medicine: dream or reality? Ann. Oncol. 2014;25(12):2304-13.
48. Allard WJ, Connelly MC, Matera J, Miller MC, Rao C, Repollet M, i sur. Tumor cells circulate inthe peripheral blood of all major carcinomas but noti n health subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897-6904.
49. Danila DC, Fleisher M, Pantel K, Scher HI. Circulating tumor cells as biomarkers:progess toward biomakrer qualification. Cancer J. 2011:5;438-450.
50. Bacceli I, Bauerle T, Holland-Letz T, Marme F, Saini M, Scharpff M, i sur.Identification of a population of blood cicrulating tumor cells from breast cancer patients that initiates in a xenograft assay. Nat Biotechnol. 2013;5:539-544.
51. Constantin T, Horswell S, Jamal-Hanjani M, Kirkizlar E, Kareht S, Pelham R, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27(5):862-7.
52. Ahronian LG, Bardelli A, Blaszkowsky LS, Corcoran RB, Corti G, Crisafulli G, et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 2016;6(2):147-153.
53. Baselga J, Gray NS, Haber DA. The evolving war on cancer. Cell. 2011;145:19-24.
54. Downing JR, McDermott U, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med. 2011;364:340-50.
55. Borresen-Dale AL, Hicks J, Navin N, Russnes HG. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011;121(10):3810-3818.
56. Mirjam Renovanz, Ella L. Kim. Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assesment. Front Oncol. 2014;4:142.
How to Cite
VULETIĆ, Filip et al. Intratumoral heterogeneity. Diagnostic Pathology, [S.l.], v. 4, n. 1, feb. 2018. ISSN 2364-4893. Available at: <>. Date accessed: 18 feb. 2018. doi:
Review Articles